Antimicrobial prophylaxis regimens following transplantation

Current Opinion in Infectious Diseases

Volumn 24, Issue 4, 2011, Pages 344-349

  Subramanian, Aruna K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antimicrobial prophylaxis; cytomegalovirus infection; hematopoietic stem cell transplantation; solid organ transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; GANCICLOVIR; IMMUNOGLOBULIN; LAMIVUDINE; MACROLIDE; MICAFUNGIN; PENICILLIN DERIVATIVE; PLACEBO; POSACONAZOLE; QUINOLONE DERIVATIVE; VALGANCICLOVIR; VORICONAZOLE;

ANTIVIRAL THERAPY; ASPERGILLOSIS; BACTERIAL INFECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMOCYSTIS; PNEUMOCYSTOSIS; PROPHYLAXIS; REVIEW; SYSTEMIC MYCOSIS; TREATMENT DURATION;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; ORGAN TRANSPLANTATION;

EID: 79960252786     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328348b379     Document Type: Review

References (35)

1. Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24:273-283.
2. Vandecasteele E, DeWaele J, Vandijck D, et al. Antimicrobial prophylaxis in liver transplant patients-a multicenter survey endorsed by the European Liver and Intestine Transplant Association. Transplant Int 2010; 23:182-190.
3. Wingard JR, Hsu J, Hiemenz JW. Hemaotopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257-272.
4. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779-795.
5. Humar A, Lebranchu Y, Vicenti F. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228-1237.
6. Kalil AC, Sun J, Florescu JF. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am J Transplant 2011; 11:18-21.
7. Snydman DR. Putting the IMPACT study into perspective: should CMV prophylaxis be extended to 6 months for high risk transplants? Am J Transplant 2011; 11:6-7.
8. Humar A. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant 2011; 11:177-178.
9. Humar A, Limaye A, Blumberg EA, et al. Extended valganciclovir prophylaxis in D\+/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90:1427-1431.
10. Blumberg EA, Hauser IA, Stanisic S, et al. Prolonged prophylaxis is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation 2010; 90:1420-1426.
11. Chou SW, Marousek G, Boivin G, et al. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 2010; 90:1409-1413.
12. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation. Ann Intern Med 2010; 152:761-769.
13. Luan FL, Kommareddi M, Ojo AO. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation 2011; 91:237-244.
14. Degertekin B, Han SB, Keefe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10:1823-1833.
15. Jiang L, Yan L, Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantaion using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10:1861-1869.
16. Gane E. Posttransplant prophylaxis strategies for hepatitis B. Am J Transplant 2010; 10:1721-1722.
17. Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11:511-517.
18. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibodypositive donors: a systematic review. Liver Transpl 2010; 16:300-307.
19. Centers for Disease Control and Prevention. Transmission of multidrugresistant Escherichia coli through kidney transplantation-California and Texas, 2009. MMWR Morb Mortal Wkly Rep 2010; 50:1642-1646.
20. Guillian JA, Cavanaugh K, Schaefer H. Lower risk of urinary tract infection with low dose trimethoprim/sulfamethoxazole compared to dapsone prophylaxis in older renal transplant patients on a rapid steroid-withdrawal immunosuppression regimen. Clin Transpl 2010; 24:636-642.
21. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 6:426-431.
22. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation: a world-wide survey. Am J Transplant 2011; 11:361-366.
23. Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54:4424-4431.
24. Johnson HJ, Han K, Capitano B, et al. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother 2010; 54:852-859.
25. Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation 2010; 90:1215-1219.
26. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143-1238.
27. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-2061.
28. Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-1416. (Pubitemid 39518200)
29. Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16:1458-1462.
30. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347. (Pubitemid 46148776)
31. Wingard JR, Carter SL, Walsh TJ, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allogeneic hematopoietic cell transplantation (HCT). Blood 2010; 116:5111-5118.
32. George B, Pati N, Gilroy N, et al. Pretransplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12:322-329.
33. Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44:471-482.
34. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110:3071-3077. (Pubitemid 350006963)
35. Erard V, Ward A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196:266-270. (Pubitemid 47047466)